Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019. Olivier spent 7 years in commercial healthcare at Eli Lilly and Sanofi Aventis leading specific Business Units. He spent 15 years within the field of neuromodulation at Medtronic, managing EMEA at Stryker NeuroVascular and serving a neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO.
Loïc Moreau has served as our Chief Financial Officer since January 2022. He is a seasoned leader with more than 20 years of experience in Finance having held senior roles at GSK notably in M&A/Corporate Development or Country-CFO across different geographies. Prior to this, he started his career at EY (External Audit) and PwC (Corporate Finance). Loic holds a master from ESSCA Management School (France) and Master in Finance from Solvay University (Belgium).
Bruno Onkelinx has 25 years of experience in highly regulated industries with the last 15 years in active implantable medical devices at Cochlear. At Cochlear he built successful teams while managing international research & development and manufacturing operations across Europe-Belgium and the US-Colorado. He led several core Cochlear products from ideation through development to commercial approval and manufacturing. During his last years at Cochlear, Bruno was leading global incubation activities supporting business development activities and external medical device start/scale-ups.
An Moonen joined Nyxoah in December 2020 as General Counsel, bringing over 20 years of experience. After 11 years at Linklaters (Corporate M&A), she joined cell therapy company TiGenix in 2011 where she oversaw all legal and compliance matters as General Counsel and Company Secretary. An was involved in various strategic licensing, financing and M&A transactions, including TiGenix’ Nasdaq IPO and its takeover by Takeda. An holds a law degree from the KU Leuven and a Master of Laws (LLM) degree from New York University School of Law. She is a member of the New York Bar.
David has more than 20 years of experience in healthcare asset management, equity research and investment banking. David held senior analysts positions at Velan Capital, Citadel and Pura Vida Investments, covering the medical devices, biotechnology and healthcare technology industries. In addition to investing in publicly traded companies at Pura Vida, he worked on private company investments. David spent several years in sellside equity research, initially covering healthcare facilities at Deutsche Bank and then medical devices at Credit Suisse. He received his B.A in Economics from Washington and Lee University.
Jeyakumar Subbaroyan has 14 years of experience in clinical and pre-clinical neuromodulation research in the fields of urology, migraine, spinal cord injury, and various chronic pain conditions. He has successfully executed multiple clinical studies across the US, Europe and Australia managing diverse global teams. He has 4 issued patents and over 20 peer-reviewed publications. Prior to Nyxoah, Jey held various positions of increasing responsibility in medical device companies including Johnson & Johnson, Spinal Modulation Inc. (acquired by St. Jude Medical), Nevro Corp. and Onward Medical Inc. to name a few.
Francis is a seasoned global regulatory and quality executive in the healthcare industry, with more than 25 years of extensive experience in the highly regulated medical device sector. He has made significant contributions to prominent organizations leading Regulatory and/or Quality functions at Medtronic, Waters, and Philips . In his responsibility as a leader in Quality and Regulatory, Francis introduced several innovative products to the market. He is known for his agility and his ability to drive innovative solutions and transformation across a wide range of therapies, markets, and products. Francis holds an MBA, and a dual bachelor’s degree in Chemistry & Biological Sciences.
Inge has more than 20 years of HR experience, joining Nyxoah from Sterigenics, where she was HR Director for the EMEAA region. At Sterigenics, her primary projects focused on organization structure, workforce planning, and compensation and benefits strategy. Prior to Sterigenics, she spent nearly 10 years at Edwards Lifesciences, where she started as an HR Manager and progressed to become a Country Manager for Benelux and HR Business Partner to the European organization.
Dorit has 13 years of experience in process manufacturing and quality management in highly regulated industries. She has successfully led both small and large groups in numerous manufacturing aspects including routine production, implementation of process changes, qualifications of new manufacturing sites and preparation to regulatory audits. She has extensive experience working in GMP and QSR/ISO 13485 regulated environments, including successful FDA, and EMA audits.
Rémi Renard has 15 years of experience in Sales and Marketing. Throughout his career he has held multiple sales and marketing positions in medical device firms, mostly in the Cardiac Rhythm Management and OSA fields at Resmed, Boston Scientific and St. Jude Medical. Notably he successfully led sales and marketing activities related to the introduction in international markets of the first to market leadless pacemaker.
Patrick Tompkins has over 20 years of executive leadership experience in the medical device space. He joined Nyxoah in 2020 as VP of US Operations with responsibility for managing Nyxoah’s US operations in their IDE trial. Patrick has previous commercial leadership experience, both with global and domestic responsibilities in the cardiac and neuro fields. The last 13 years with neuromodulation companies, 8 of which were with St Jude Medical. Patrick has introduced and led the commercialization efforts, of first to market innovative technologies in both the cardiac and the neuromodulation spaces.